Introduction: NRG Oncology RTOG 0937 is a randomized phase II trial evaluating 1-year overall survival (OS) with prophylactic cranial irradiation (PCI) or PCI plus consolidative radiation therapy (PCIþcRT) to intrathoracic disease and extracranial metastases for extensive-disease SCLC.
Introduction
SCLC comprises approximately 13% of lung cancers diagnosed in the United States. Most patients with SCLC have metastatic disease. 1 Primary therapy for extensivedisease (ED) SCLC is four to six cycles of platinum-based chemotherapy followed by prophylactic cranial irradiation (PCI) in select patients. Although response rates to chemotherapy are high at 60% to 70%, time to progression and median survival are modest (4-6 months and <10 months, respectively). 1, 2 Response and improvement in survival is limited for second-line chemotherapy, particularly if progression occurs within 30 to 90 days. 3, 4 PCI has been shown to decrease brain metastases and improve 1-year overall survival (OS) in patients who respond to chemotherapy. 5 The use of consolidative thoracic radiation for ED SCLC remains controversial even though it has been shown to improve survival and locoregional control in both prospective randomized trials 6, 7 and retrospective reviews. 8, 9 NRG Oncology RTOG 0937 was designed to address a select patient population with oligometastitc SCLC (one to four distant metastases) with consolidative radiation therapy (cRT) to the locoregional thoracic disease and active sites of metastases after chemotherapy. The underlying hypothesis was that delaying progression of disease with radiation therapy (RT) will delay progression and improve OS in this favorable patient population.
We conducted a randomized phase II trial designed to evaluate PCI alone or PCI and cRT (PCIþcRT) to intrathoracic disease and limited extracranial metastases in patients with oligometastatic SCLC.
Materials and Methods

Patient Selection
NRG Oncology RTOG 0937 was a two-arm randomized phase II study designed to assess whether the use of PCIþcRT would improve OS compared with PCI alone for patients with ED SCLC. Protocol approval was received from the institutional review board at each study site. Informed consent was obtained from each patient before participation. Patients were randomly assigned to receive PCI or PCIþcRT to their intrathoracic disease and residual metastases. Eligible patients had pathologically proven SCLC without brain metastases and with one to four extracranial metastases at diagnosis based on computed tomography (CT) scan of the chest/ abdomen and bone scan or positron emission tomography (PET)/CT. Brain imaging was not required before chemotherapy in the absence of symptoms but was required before randomization. Eligible patients had a partial response (PR) or complete response (CR) to four to six cycles of platinum-based chemotherapy at a minimum of one site of disease and no evidence of progression at any site. Restaging was required within 8 weeks of study entry. Imaging included CT of the chest/ abdomen or PET/CT, bone scan or PET, and magnetic resonance imaging (MRI) of the brain (or CT if MRI was contraindicated). Other eligibility criteria included Zubrod performance status of 0 to 2, serum aspartate transaminase and aspartate transaminase levels within 2.5 times the upper limit of normal (ULN) and bilirubin level less than 1.5 times the ULN within 1 week before study entry for patients with liver metastases, serum creatinine level less than 1.5 times the ULN for patients with renal or perirenal metastases, absolute neutrophil count of 1000 cells/mm 3 or higher, platelet count of 75, 000 cells/mm 3 or higher, and hemoglobin level of 8 g/dL or higher.
Treatment
All patients were to receive 25 Gy of PCI at 2.5 Gy per fraction. In arm 2, thoracic radiation therapy to the primary and involved regional nodes was required for all patients unless they had had palliative radiation therapy to the primary at diagnosis. Radiation was delivered to postchemotherapy volumes, including to the site of the primary and involved nodal regions at diagnosis. Metastases were treated if they did not have a CR to chemotherapy. The recommended radiation dose to all extracranial sites was 45 Gy delivered in 15 daily fractions of 3 Gy. From 30 to 40 Gy was acceptable if dose reduction was necessary to meet normal tissue dose constraints. It was recommended that PCI be started concurrently with cRT, although sequential therapy was allowed at the discretion of the treating physician.
Patients were evaluated after therapy at 2 weeks; at 1, 2, 6, 9, and 12 months; every 6 months for 2 to 3 years; and then annually. CT of the chest/abdomen or PET/CT and brain imaging were required at each visit starting at 2 months.
Statistical Analysis
The study was designed to detect a 33.7% relative reduction in the risk of death (hazard ratio [HR] ¼ 0.663) in the PCIþcRT group as compared with in the PCI-alone group at the significance level of 0.1 (one sided) with 80% power. On the basis of the aforementioned, a total of 112 events and a sample size of 146 were required. Adjusting for an ineligibility or insufficient follow-up rate of up to 5%, the final targeted accrual was 154. Two interim analyses and a final analysis were planned for early stopping for efficacy and futility when 37 and 75 deaths from both arms were observed. The efficacy testing was based on the power family of test 10 with D ¼ 0, and the futility testing boundary was based on rule C (at a nominal significance level of 0.005) as proposed by Freidlin and Korn. 11 The NRG Oncology/RTOG Data Monitoring Committee oversaw the interim monitoring. Patients were equally randomized into the two arms on the basis of Zelen's allocation scheme and stratified by response to treatment (CR versus PR), number of metastases (1 versus 2-4), and age (<65 versus 65 years [added on July 15, 2014] ). Age was added as a stratification factor at the recommendation of the data monitoring committee when an unbalanced distribution between treatment arms was observed without knowledge of efficacy information.
All outcome times were calculated from the date of randomization to the date of event or, if no event, the date of last follow-up. For OS, the event was death due to any cause. The Kaplan-Meier method 12 was used to estimate OS rates. For time to progression, the event was the first occurrence of recurrence/progression of preexisting disease (regardless of prior response or treatment with RT) or development of new metastases. Death without failure was considered as a competing risk. Actual rates of time to progression were estimated using the cumulative incidence method 13 by taking into account competing risks. The log-rank test 14 was used to compare OS event rates between treatments. The Cox regression model 15 was used to compare the treatment differences. For time to progression, competing risk events (death without progression) were censored at the time of competing event per the cause-specific competing risks analysis method. 16 Adverse events were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
Results
The study opened to accrual on March 18, 2010, and closed February 27, 2015 . A planned interim analysis indicated that the study crossed the futility boundary for the primary end point and was closed before meeting the accrual target of 154 patients. The final analysis was performed in August 2015, with a median follow-up of 9 months, on the basis of all data received at the NRG Oncology Statistics and Data Management Center through July 15, 2015. A total of 97 patients from 57 participating sites were randomized. Eleven patients were ineligible and excluded from analysis (nine patients randomized to receive PCI and two to receive PCIþcRT). Reasons for ineligibility included failure to receive protocol therapy (two patients), inability to confirm eligibility (two patients), testing completed outside the required time frame (four patients), brain metastases (one patient), chemotherapy completed more than 8 weeks from study entry (one patient), and platelet count outside the required range (one patient). Of the 86 patients included in the analysis, 42 were randomized to receive PCI and 44 to receive PCIþcRT (Fig. 1) .
Pretreatment characteristics were evenly distributed, with the exception of age (Table 1 ): 54.5% of patients randomized to the PCIþcRT arm and 38.6% of those randomized to the PCI arm were 65 or older (p ¼ 0.03). The rate of CR to chemotherapy (before study entry) in the primary lung tumor was 15.9% and the PR rate was 68.1%. Of the participating patients, 36% had one metastasis and 36%, 15.1%, and 12.8% had two, three, and four metastases, respectively. The median time from diagnosis to start of radiation was 22 weeks for each group. The median times from end of chemotherapy to start of radiation were 5.9 weeks and 6.9 weeks for PCI and PCIþcRT, respectively.
Among the patients receiving PCIþcRT, two (4.5%) did not have thoracic RT. Treating physicians withheld radiation on account of CR (one patient) and anticipated poor tolerance (one patient). Of the patients treated with cRT, 90.5% received thoracic radiation per protocol (30-45 Gy). Two patients received less than 30 Gy (22.5 Gy and 24 Gy) and two patients received more than 45 Gy (50 and 65 Gy), with 95.3% of all patients receiving PCI per protocol.
At the time of this analysis, 51 deaths, including 22 with PCI and 29 with PCIþcRT, were reported. The 1-year OS rates were 60.1% (95% confidence interval [CI]: 41.2-74.7] for PCI and 50.8% (95% CI: 34.0-65.3) for PCIþcRT (Fig. 2) . Median survival was 15.8 months for PCI and 13.8 months for PCIþcRT. The two-sided log-rank test p value was 0.21, and the unadjusted HR was 1.44 (HR favors PCI, 95% CI: 0.82-2.53). Most patients died of disease progression (76.5%). Patients with a CR to chemotherapy at all sites of disease appeared to have a better survival outcome than those with a PR (at any site), with an HR of 2.1 (HR favors CR, 95% CI: 0.97-4.56, p ¼ 0.06). Because of the limited sample of patients with CR (all sites), PCI (10 patients), and PCIþcRT (seven patients), it was not possible to determine whether PCIþcRT had a differential treatment effect over PCI alone between patients with a CR and those with a PR.
There were 32 patients with progression in the PCI arm and 31 in the PCIþcRT arm. The 3-month and 1-year rates of any progression were 53.3% (95% CI: 36.3-67.7) and 79.6% (95% CI: 60.6-90.2) for PCI and 14.5% (95% CI: 5.8-27.0) and 75.0% (95% CI: 57.9-86.0) for PCIþcRT. The difference in the distribution of time to progression was statistically significant (log-rank test p ¼ 0.01), with a hazard ratio 0.53 (HR favors PCIþcRT, 95% CI: 0.32-0.87) (Fig. 3 ). There were only two and four deaths without progression with PCI and PCIþcRT, respectively. Patients with a CR (all sites) had a longer time to progression than those with a PR (any site) (HR ¼ 2.08, 95% CI: 1.04-4.17, p ¼ 0.04). Median progression-free survival was 2.9 months (95% CI: 2.4-3.7) for PCI and 4.9 months (95% CI: 3.4-6.0) for PCIþcRT (p ¼ 0.0148).
First site of failure was in the sites present at diagnosis in 25 patients with PCI (78.1%) and 13 patients with PCIþcRT (41.9%) ( Table 2 ). First site of failure at sites of locoregional disease was reported in 20 patients with PCI (62.5%) and eight patients with PCIþcRT (25.8%). New sites of disease (not present at diagnosis) were reported in 10 of the 32 patients in the PCI arm (31.3%) and 19 of the 31 patients in the PCIþcRT arm who progressed (61.3%). First site of failure occurred outside radiation fields in 17 patients who received PCIþcRT (54.8%). In patients treated with PCIþcRT there were 10 first failures in the consolidative radiation fields (other than the brain) (32.3%) and four first failures in the brain only (12.9%). The 1-year cumulative incidences of brain metastases were 17% (95% CI: 6.6-40.2) and 18.5% (95% CI: 8.5-37.6) with PCI and PCIþcRT, respectively. The brain was a component of first failure in six of the 31 patients with failures in the PCIþcRT arm (19.4%) and in none of the 32 patients in the PCI-only arm. Grade 3 or higher adverse events regardless of attribution to protocol therapy occurred in 10 patients treated with PCI (23.8%) and 16 treated with PCIþcRT (36.4%) (p ¼ 0.24). Grade 3 or higher toxicity attributed to therapy was reported in four patients treated with PCI (9.5%) and 11 treated with PCIþcRT (25%). Grade 3 toxicity with PCIþcRT included decreased blood counts, esophageal symptoms, tachycardia, fatigue, and respiratory symptoms. Grade 4 dyspnea and tracheal stenosis was reported in one patient treated with PCI only (2.4%) and no grade 5 toxicity was attributed to therapy with PCI. Two patients (4.5%) had grade 4 toxicity and one (2.3%) had grade 5 toxicity attributed to treatment with PCIþcRT. Grade 4 toxicity included hypoxia and respiratory failure during treatment and decreased platelet count at 12 days after therapy. Grade 5 pneumonitis attributed to therapy was reported in one patient treated with PCIþcRT. This patient received 42 Gy to the chest, with 37% of the lung receiving 20 Gy or more, which exceeded protocol normal tissue dose constraints (Table 3) .
Discussion
Thoracic radiation and PCI have been shown to decrease the incidence of locoregional failures and brain metastases and improve survival in both limited-disease (LD) SCLC 17, 18 and ED SCLC. [5] [6] [7] Although multimodality therapy for LD SCLC is the standard of care, it remains controversial for ED SCLC. Patients with good response to chemotherapy and limited metastatic disease are the patients with ED SCLC who are most likely to benefit from multimodality therapy. NRG Oncology RTOG 0937 was conducted to assess a potential survival advantage of consolidative extracranial irradiation in patients with oligometastatic ED SCLC. Although this was not a positive trial, there were several important findings: the first failure after chemotherapy is likely to occur in sites of presenting disease, radiation therapy to these sites alters failure patterns, late radiation therapy without concurrent chemotherapy is not durable, and oligometastatic ED SCLC survival approaches that of LD SCLC. Ineffective radiation dose and schedule, advanced age, and an imbalance in disease burden in the two groups all likely contributed to the lack of survival advantage with cRT in this trial.
Survival
Early randomized studies showed a survival advantage with thoracic radiation in addition to chemotherapy for LD SCLC. 19, 20 These early LD SCLC studies did not include the routine use of CTs and were conducted before the era of PET/CT and MRI; therefore, many patients likely had unrecognized ED SCLC. The routine use of PET/CT has been shown to increase stage in 8% to 18% of patients. 21, 22 Thoracic radiation for ED SCLC was supported by the Jeremic trial reported in 1999, which showed a survival advantage in patients with ED SCLC treated with thoracic radiation. 7 Despite compelling data, the routine use of thoracic radiation in ED SCLC has not been regarded as standard of care. However, many clinicians have selectively used thoracic radiation and have published outcomes in several retrospective reviews published since initiation of the current trial. These retrospective reviews and database analyses have shown improvement in survival with thoracic radiation (Table 4) . [6] [7] [8] [9] The CREST trial, conducted in the Netherlands and the United Kingdom, was conducted during the same time as the current trial. It included 495 patients with ED SCLC who were randomly assigned to PCI or PCI and thoracic radiation (30 Gy in 10 fractions) after response to chemotherapy. The number of metastases was not limited. OS at 1 year was the primary end point. The 1-year OS rate was not different between the two groups, with 33% (95% CI 27-39) for thoracic radiation versus 28% (95% CI 22-34) for observation (HR ¼ 0.84, 95% Additional analysis of CREST to identify patients who may have benefitted most from thoracic radiation showed that thoracic radiation led to a significant difference in overall and progression-free survival in patients who had residual intrathoracic disease after chemotherapy. In these patients, the difference in OS was statistically significant (p ¼ 0.03, HR ¼ 0.81, 95% CI: 0.66-0.98 [stratified]). They concluded that thoracic radiation should be offered to patients with a good response or PR after chemotherapy, but not to those with thoracic CR. 23 There were too few patients in NRG Oncology RTOG 0937 to perform this analysis.
The trial published by Jeremic et al. in 1999 supported thoracic radiation for ED SCLC in patients with at least a PR to locoregional disease and a CR to extrathoracic sites with chemotherapy. 7 As in NRG Oncology RTOG 0937, most patients had one or two sites of metastases at diagnosis, although this was not a requirement. Unlike in NRG Oncology RTOG 0937, patients with good response to the first three cycles of chemotherapy received high-dose radiation therapy to the primary locoregional disease only with concurrent chemotherapy. Patients were treated initially with three cycles of cisplatin and etoposide. Those with a CR or PR locally and a CR at distant sites were treated with two cycles of were improved in the RT group. The investigators did not describe a difference between patients with and without residual disease in the chest after chemotherapy. Distant metastatic rate remained high in both groups. The pattern of failure relative to initial pattern of distant disease was not described. 7 An important finding in NRG Oncology RTOG 0937 is that the median OS (15.8 months) and 1-year OS (60.1%) (95% CI: 41.2-74.7) in the PCI arm in NRG Oncology RTOG 0937 exceeded what was predicted with chemotherapy and PCI for ED SCLC. For comparison, the median survival with chemotherapy and PCI was 15.8 months compared with 8 months in the CREST trial. Both of these trials calculated survival from randomization, which was after four to six cycles of chemotherapy and restaging. In NRG Oncology RTOG 0937 the median time from diagnosis to start of radiation was more than 4 months. The median survival in the Jeremic trial with chemotherapy and PCI alone for patients with CR to distant sites was 11 months from randomization, which was before the start of chemotherapy. Additionally, the median survival of NRG Oncology RTOG 0937 compares favorably to the median survival of the intergroup trial for limited disease small cell lung cancer, comparing concurrent chemotherapy with 45 Gy in 1.8 Gy daily to 1.5 Gy twice daily fractions. The median survival measured from prior to chemotherapy was 19 and 23 months, respectively. 24 The design of NRG Oncology RTOG 0937 intentionally included a favorable patient population with oligometastases by rigorous staging at diagnosis and after chemotherapy. Perhaps a more appropriate treatment for this patient population with low-volume systemic disease is early radiation concurrent with cycle 3 or 4 of chemotherapy in patients with a favorable response to cycles 1 and 2 of chemotherapy followed by PCI, which is similar to the treatment regimen in the Jeremic trial.
Concurrent chemotherapy and radiation has been shown to be superior to sequential therapy. 17 The importance of the early use of RT in LD SCLC was demonstrated in the National Cancer Institute of Canada Clinical Trials Group study in 1993. 25 Patients were randomized to begin thoracic radiation on week 3 or 15 of chemotherapy. Patients without progressive disease received PCI after chemotherapy and radiation. Progression-free survival (p ¼ 0.036) and OS (p ¼ 0.008) were superior with early thoracic radiation. Additionally, patients with late radiation had a higher risk of brain metastases. 25 A subsequent meta-analysis was undertaken by De Ruysscher et al. to identify time factors for combined chemotherapy and radiotherapy that may influence OS. 26 The time from first day of chemotherapy to last day of RT (start of chemotherapy to end of radiation [SER] ) was the most important predictor of outcome. There was a significantly higher 5-year survival rate in the shorter SER arms (relative risk [RR] ¼ 0.62; 95% CI; 0.49-0.80; p ¼ 0.0003), which was more than 20% when the SER was less than 30 days (upper bound of 95% CI ¼ 90 days). 20 For comparison, the SER for NRG Oncology RTOG 0937 was well in excess of 150 days.
Failure Patterns
Brain failures have been well described and reported, although extracranial failure patterns after chemotherapy have not been reported in detail. It is intuitive that the most likely site of failure after chemotherapy for ED SCLC is in areas of measurable disease at diagnosis, particularly sites without a CR to chemotherapy. In the landmark trial showing an improvement in 1-year OS with PCI in patients with ED SCLC published by Slotman et al., the chest was the most likely site of progression. 5 Persistent intrathoracic disease was present in 75% of patients after chemotherapy, and approximately 90% had intrathoracic progression in the first year. The CREST trial, evaluating thoracic radiation therapy after chemotherapy was a natural follow-up to this trial. 6 Unlike the CREST trial, NRG Oncology RTOG 0937 included consolidative RT to distant metastases in addition to thoracic radiation, and it was the first study to evaluate outcomes and report failure patterns in patients with oligometastatic ED SCLC.
Patients on NRG Oncology RTOG 0937 were more likely to fail in sites of disease present at diagnosis. Fewer patients in the PCIþcRT arm had their locoregional disease as a component of first failure (25.8% versus 62.5%). Progression at presenting sites of disease was higher with PCI (78.1%) than with PCIþcRT (41.9%). As in NRG Oncology RTOG 0937, patients on the CREST trial had a lower rate of isolated intrathoracic progression with thoracic radiation (19.8%) than the rate of 46% in the observation arm (p < 0.0001). 6 Likewise, local recurrence-free survival in the Jeremic trial at 5 years was 20% with RT and 8.1% with chemotherapy only (p ¼ 0.062). 7 Early concurrent chemotherapy and highdose radiation therapy in the Jeremic trial likely contributed to favorable local recurrence-free survival.
An unexplained finding in the current trial was more new sites of disease and first failures in the brain with PCIþcRT than with PCI alone. There was not a clear explanation for this based on site, volume, and number of metastases. Higher brain failures and new sites of disease suggest that there was an unaccounted for imbalance in systemic disease burden that decreased the likelihood of seeing a survival advantage with PCIþcRT.
Although consolidative radiation to locoregional disease and residual metastases after chemotherapy delayed progression at 3 months, this benefit was not durable. The 3-month rate of progression was 53.3% with PCI but only 14.5% with PCIþcRT, although by 1 year the progression rates were not different (79.6% and 75%, respectively). A more aggressive course of radiation therapy would have likely resulted in a more durable response. PCI remains controversial in the treatment ED SCLC despite the survival advantage at 1 year demonstrated by Slotman et al. 5 and the advantages of PCI in early trials with subset analysis of patients with ED. 18 Adding to this controversy is a recent Japanese trial that did not show a survival benefit with PCI. 27 PCI has consistently been shown to be effective for decreasing brain failures, although which patients will derive a survival benefit is not completely clear. Extent of disease at diagnosis, chemotherapy response, and immunotherapy response, are important considerations. Treatment of active extracranial disease is likely to also play an important role, as active extracranial disease will continue to seed the brain after PCI.
Toxicity
NRG Oncology RTOG 0937 was closed early because of a futility analysis showing that a survival advantage in the study arm was unlikely. Unfortunately, unofficial communications and discussions have suggested that there was excess toxicity on this trial. Toxicity in NRG Oncology RTOG 0937 was as anticipated with the therapy delivered ( Table 3) . The rates of grade 3þ toxicity were 23% for PCI and 36% for PCIþcRT (p ¼ 0.24). Grades 4 and 5 toxicity included hematologic and pulmonary toxicity. There was one death attributed to protocol therapy. This patient had radiation-induced pneumonitis. The radiation dose to normal lung exceeded the dose constraints required by protocol. This emphasizes the importance of careful attention to minimizing the radiation dose delivered to normal tissues. Toxicity in NRG Oncology RTOG 0937 compares favorably to that reported in other trials evaluating thoracic RT for ED SCLC and LD SCLC. Jeremic et al. reported rates of grade 3 and grade 4 esophageal toxicity of 20% and 7%, respectively, and a 5% rate of grade 3 bronchopulmonary toxicity with radiation, which is similar to the rates in CREST.
6,7 Future studies should encourage or require use of RT techniques such as intensity-modulated radiation therapy and stereotactic body radiation therapy to minimize the dose to normal tissues, including bone marrow, and thus minimize hematologic toxicity and improve tolerance to systemic therapy.
Conclusion
Patients with ED SCLC represent a diverse patient population with a wide range of anticipated outcomes. There is no one appropriate treatment regimen for all patients. This study was the first to prospectively evaluate the favorable population with oligometastatic SCLC. Consolidation radiation therapy delayed progression and altered failure patterns in this population. Toxicity was as anticipated with the therapy delivered and similar to published data. The lack of benefit seen with PCIþcRT in this very favorable cohort of patients with ED SCLC may be due to lack of optimal timing, dose, and fractionation of radiation therapy. This study has demonstrated that this favorable subpopulation of patients with ED SCLC has an OS similar to that of patients with LD SCLC. Future trials for this population should focus on timing, dose, and fractionation of radiation therapy delivery.
